Souhaitez-vous accéder aux communiqués récents ?

Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® ...

Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label ...

US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated...

Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials   The global clinical program will...

First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Glivec®*  First genomic analysis and 3-year...

Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at...

Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen   Paul Hudson und Bruno Strigini werden in die...

Paul Hudson devient CEO de Novartis Pharmaceuticals et Bruno Strigini devient CEO de Novartis Oncology ; David Epstein quitte Novartis   Paul Hudson et Bruno Strigini sont nommés au Comité de...

Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis  Paul Hudson and Bruno Strigini appointed to the...

Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the...